The author addresses critical issues to consider prior to performing forced degradation studies and provides best practice recommendations for these types of studies.
Anette Skammelsen Schmidt
Advertisement
Articles by Anette Skammelsen Schmidt
Advertisement
Latest Updated Articles
Forced Degradation Studies for BiopharmaceuticalsJuly 1st 2016
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
2
Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy
3
BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding
4
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
5